Design Therapeutics Stock News

Sorry to be the bearer of bad news, but Design Therapeutics (NASDAQ: DSGN ) has good intentions and less-than-stellar financials. Design Therapeutics may be a pioneer in the field of genomic medicine

Short squeeze stocks are the talk of Wall Street at the moment. As the banking crisis continues to unfold, some investors are seeking refuge by betting against many well-known losers — and reaping t

Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-

CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to

Topline Data from Phase 1 Trial Expected in the Second Half of 2022

Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon

Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and Restored Normal Splicing In Vitro, Supporting Further Development Treatment with GeneTAC™ Small Molecules Reduced Nuclear Foci and

Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that Jo

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET.

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that Joã

Design Therapeutics (DSGN) announced the appointment of Jae Kim, M.D., as the companys new Chief Medical Officer.Before joining Design (DSGN), Dr

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN ) with a Sell rating and a $10 price target. The analyst Madhu Kumar has caution about the Company''s lead indication of Friedreich ataxia. Natural history studies provide little support that differences in FXN levels will shift the FA disease course. At the same time, high-dose nicotinamide has already achieved clinically meaningful FXN induction with the minimal observed change in Full story available on Benzinga.com

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar has caution about the Company's lead indication of F